Anixa Biosciences Announces University of Maryland School of Medicine to Join Cchek™ Prostate Cancer Study
SAN JOSE, Calif., Sept. 23, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system to fight cancer, today announced that Mohummad Siddiqui, MD, Associate Professor of Surgery at the University of Maryland School of Medicine (UMSOM) has joined its ongoing prostate cancer Cchek™ study.
UMSOM is one of several sites across the United States participating in this study. Study enrollment will be led by Dr. Mohummad Siddiqui, who is also the Director of Urologic Oncology and Robotic Surgery and Chief of Urology at the Baltimore VA Medical Center.
"We are pleased to be working with Dr. Siddiqui and the University of Maryland School of Medicine to further develop our artificial intelligence based prostate cancer diagnostic test," stated Dr. Amit Kumar, President and CEO of Anixa Biosciences. "Significant progress has been made in our efforts to advance the Cchek™ Prostate Cancer Confirmation test toward commercial launch later this year. We believe the Cchek™ early cancer detection platform will make a great impact on patient care, and we are pleased by the continued additions to our team of collaboration partners."
About Anixa Biosciences, Inc.
Anixa is a publicly-traded biotechnology company focused on harnessing the body's immune system in the fight against cancer. Anixa's therapeutic portfolio includes a cancer vaccine technology focused on the immunization against α-Lactalbumin to prevent triple negative breast cancer (TNBC), as well as a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor t-cell (CER-T) technology. The company's diagnostic portfolio consists of Cchek™, a liquid biopsy technology for early detection of solid tumors based on the body's immune response to the presence of a malignancy. Anixa continually examines emerging technologies in complementary fields for further development and commercialization. Additional information is available at www.anixa.com.
About the University of Maryland School of Medicine
Now in its third century, the University of Maryland School of Medicine was chartered in 1807 as the first public medical school in the United States. It continues today as one of the fastest growing, top-tier biomedical research enterprises in the world, with 43 academic departments, centers, institutes, and programs. The School of Medicine has a faculty of more than 3,000 physicians, scientists, and allied health professionals, including members of the National Academy of Medicine and the National Academy of Sciences, and a distinguished recipient of the Albert E. Lasker Award in Medical Research. With an operating budget of more than $1.2 billion, the School of Medicine works closely in partnership with the University of Maryland Medical Center and Medical System to provide research-intensive, academic and clinically based care for more than 1.2 million patients each year. The School has over 2,500 students, residents, and fellows, and nearly $575 million in extramural funding, with most of its academic departments highly ranked among all medical schools in the nation in research funding. As one of the seven professional schools that make up the University of Maryland, Baltimore campus, the School of Medicine has a total workforce of nearly 7,000 individuals. The combined School and Medical System ("University of Maryland Medicine") has an annual budget of over $6 billion and an economic impact of more than $15 billion on the state and local community. The School of Medicine faculty, which ranks as the 8th highest among public medical schools in research productivity, is an innovator in translational medicine, with 600 active patents and 24 start-up companies. The School works locally, nationally, and globally, with research and treatment facilities in 36 countries around the world. Visit medschool.umaryland.edu.
Forward-Looking Statements: Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.
Sharen Tilman (Investors)
Johanna Bennett (Media)
View original content to download multimedia:http://www.prnewswire.com/news-releases/anixa-biosciences-announces-university-of-maryland-school-of-medicine-to-join-cchek-prostate-cancer-study-300922712.html
SOURCE Anixa Biosciences, Inc.
Released September 23, 2019
Sign up for email Updates
Be The First to Receive Breaking NewsSign Up Now